Perspective Therapeutics says first patient dosed in Phase 1/2a trial of VMT01
Perspective, Therapeutics (CATX) announced that the first patient was dosed in a new cohort of a Phase 1/2a trial evaluating the safety of ...
Rheumatology Advisor1h
February 2025 Recap: Drug Pipeline Updates
The table is a review of notable updates that occurred in February 2025 for investigational products in development.
Perspective Flat on New Drug Trials
Perspective Therapeutics, Inc. (NYSE: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, announced today that the first patient ...
Event-Based Cameras - Not All Pixels Are Important
Asynchronous, event-based sensing is a new paradigm in computer vision, enabling lower data bandwidth, decision latency, ...
Medscape4h
Evidence Growing That GLP-1RAs May Reduce COPD Exacerbations and Risks for Other Lung Diseases
Emerging evidence shows glucose-lowering medications may have the potential to improve chronic obstructive pulmonary disease ...